Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2024
AbbVie completes acquisition of ImmunoGen
AbbVie announced that it had completed its previously announced acquisition of ImmunoGen.
2022
FDA grants accelerated approval for Elahere
The US Food and Drug Administration granted accelerated approval for ImmunoGen’s Elahere to treat specified adult patients with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.